Ebola virus disease kills faster than almost any pathogen that has caused a major outbreak in the modern era. With case fatality rates between 25% and 90% depending on the strain and setting, it is among the most lethal infectious diseases known. Yet every Ebola outbreak in history has been stopped. Understanding how requires looking at the full arc, from the virus's discovery in 1976 to the ring vaccination strategy that changed everything in the late 2010s.

How was Ebola discovered?

In September 1976, a mysterious hemorrhagic illness appeared near the Ebola River in what was then Zaire (now the Democratic Republic of the Congo). The village of Yambuku and its surrounding communities saw 318 cases. 280 people died, an 88% case fatality rate.

Belgian microbiologist Peter Piot was 27 years old when a blood sample from a Flemish nun who had died in Yambuku arrived at his lab in Antwerp. He and his colleagues isolated a virus that looked like Marburg under the electron microscope but was clearly something different. They named it after the Ebola River to avoid stigmatizing Yambuku itself.

A simultaneous but smaller outbreak occurred in Nzara, Sudan, caused by a different species of the same virus. Between the two outbreaks, the world had its introduction to Ebola: 602 cases, 431 deaths.

Why were outbreaks small for 40 years?

After 1976, Ebola appeared sporadically in central Africa but never spread widely. Between 1976 and 2013, approximately 24 known outbreaks occurred, most involving fewer than 400 cases. The largest was the 2000-2001 Uganda outbreak with 425 cases and 224 deaths. Several outbreaks were contained at under 100 cases.

Geography played a major role. Ebola's animal reservoir, likely fruit bats of the Pteropodidae family, lives in remote tropical forest regions. Spillover events typically happened in small, isolated villages. Patients became severely ill so quickly that they rarely traveled far before becoming incapacitated. Local burial practices that involved washing the dead (a major transmission route) kept the virus circulating within tight community networks.

Isolation and contact tracing, the basic tools of outbreak response, worked because the outbreaks burned through small communities and ran out of susceptible contacts before reaching cities. The virus's brutality was, paradoxically, a containment advantage.

What went wrong in West Africa?

In December 2013, a 2-year-old boy named Emile Ouamouno fell ill in the village of Meliandou in southeastern Guinea. He likely contracted Ebola from contact with bats. He died on December 6. His 3-year-old sister, mother, and grandmother all died within weeks. By the time Ebola was identified as the cause in March 2014, it had already spread to Guinea's capital, Conakry.

What followed was catastrophic. By the time the outbreak was declared over in June 2016, Guinea, Sierra Leone, and Liberia had recorded 28,616 cases and 11,325 deaths. The numbers dwarfed every previous Ebola outbreak combined.

Three factors turned a village outbreak into a regional disaster.

Broken health systems. Guinea, Sierra Leone, and Liberia had roughly 1 to 2 doctors per 100,000 people. Compare that to the US at approximately 260 per 100,000. Clinics lacked basic supplies. Health workers had no training in hemorrhagic fever protocols. Patients showing up at understaffed clinics infected healthcare workers, who then infected other patients.

Distrust of authorities. Decades of civil war in Sierra Leone and Liberia had shattered trust between communities and government institutions. When health teams arrived to isolate patients and safely bury the dead, many communities resisted. Some believed the teams were actually spreading the disease. Violence against response workers occurred repeatedly.

Delayed international response. MSF (Doctors Without Borders) raised the alarm in March 2014. WHO didn't declare a Public Health Emergency of International Concern until August 8, 2014, five months later. By then the outbreak was growing exponentially. An internal WHO review later acknowledged the delay was a critical failure.

Containment ultimately required a military-scale response: treatment centers built by US, UK, and French forces, over 50,000 community health workers in Sierra Leone alone, and massive safe burial campaigns.

How did ring vaccination change the game?

During the DRC's 10th Ebola outbreak in 2018-2020, responders deployed a new weapon: the rVSV-ZEBOV vaccine (brand name Ervebo), using a strategy called ring vaccination.

Ring vaccination doesn't attempt to vaccinate an entire population. Instead, when a new case is confirmed, response teams identify every person who had contact with the patient, and then every person who had contact with those contacts. This "ring" of people receives immediate vaccination. The strategy creates a firewall of immune individuals around each case, cutting transmission chains without needing to reach everyone.

The concept dates back to the smallpox eradication campaign of the 1960s and 1970s. Applying it to Ebola required a vaccine that worked fast. rVSV-ZEBOV generates protective immunity within about 10 days and showed 97.5% efficacy in a landmark 2015 trial in Guinea.

During the 2018-2020 DRC outbreak, which affected conflict zones in North Kivu and Ituri provinces, over 303,000 people received ring vaccination. Despite extraordinarily difficult conditions (armed groups attacked treatment centers, community resistance was widespread, and the region was simultaneously experiencing armed conflict), the outbreak was contained at 3,481 cases and 2,299 deaths. Without the vaccine, models suggest the toll would have been far higher.

What tools exist now?

Ebola response has improved dramatically since 2014. Two vaccines are now prequalified by WHO. Ervebo (rVSV-ZEBOV) by Merck provides single-dose protection against the Zaire species, which has caused the most lethal outbreaks. Zabdeno/Mvabea by Johnson & Johnson is a two-dose regimen approved in the EU for preventive vaccination.

Treatments have also advanced. The monoclonal antibody combination Inmazeb (atoltivimab, maftivimab, and odesivimab) received FDA approval in 2020 after a clinical trial in DRC showed it reduced mortality from 49% to 34% among treated patients. Ebanga (ansuvimab), another monoclonal antibody, also showed significant survival benefit.

Still, challenges remain. Vaccine stockpiles are limited. DRC has averaged roughly one Ebola outbreak every two years since 2017, and maintaining cold-chain storage for vaccines in remote equatorial forest settings is logistically brutal. Contact tracing requires community cooperation, which is hardest to achieve in exactly the areas where outbreaks tend to occur: regions marked by poverty, conflict, and institutional distrust.

How does PandemicAlarm rate Ebola?

PandemicAlarm assigns Ebola virus disease a baseline severity rating of 4/5. The high CFR, lack of widespread population immunity, and limited treatment access in endemic regions all contribute to that rating. Active outbreaks with evidence of urban spread or international cases would push the rating to 5/5.

Ebola is not likely to cause a global pandemic on the scale of influenza or COVID-19. It spreads through direct contact with bodily fluids, not through the air, which limits its transmission efficiency. But every new outbreak tests local and international response capacity. West Africa proved that a delayed response to even a "familiar" pathogen can cost thousands of lives.

Track active Ebola events on the PandemicAlarm map and read more about how related hemorrhagic fever viruses behave in our Marburg virus explainer.